{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:13:58Z","timestamp":1762503238436,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T00:00:00Z","timestamp":1667088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ctro.2022.10.014","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T04:12:57Z","timestamp":1667448777000},"page":"155-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Feasibility of low-dose radiotherapy for patients with stage I\/II extranodal NK-\/T-cell lymphoma, nasal type achieving complete response after l-asparaginase-containing chemotherapy"],"prefix":"10.1016","volume":"38","author":[{"given":"Jae Sik","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noorie","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Il Han","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Kyung","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Hyun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctro.2022.10.014_b0005","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ijrobp.2011.02.039","article-title":"Mild toxicity and favorable prognosis of high-dose and extended involved-field intensity-modulated radiotherapy for patients with early-stage nasal NK\/T-cell lymphoma","volume":"82","author":"Wang","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2022.10.014_b0010","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13045-018-0687-0","article-title":"Treatment of localized extranodal NK\/T cell lymphoma, nasal type: a systematic review","volume":"11","author":"Kim","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.ctro.2022.10.014_b0015","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1","article-title":"Frequent expression of P-glycoprotein\/MDR1 by nasal T-cell lymphoma cells","volume":"76","author":"Yamaguchi","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.ctro.2022.10.014_b0020","first-page":"177","article-title":"Sequential chemoradiotherapy for stage I\/II nasal natural killer\/T cell lymphoma","volume":"22","author":"Noh","year":"2004","journal-title":"Rad Oncol J"},{"issue":"1","key":"10.1016\/j.ctro.2022.10.014_b0025","doi-asserted-by":"crossref","DOI":"10.1186\/1756-8722-6-44","article-title":"A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK\/T-cell lymphoma, nasal type","volume":"6","author":"Lin","year":"2013","journal-title":"J Hematol Oncol"},{"issue":"30","key":"10.1016\/j.ctro.2022.10.014_b0030","doi-asserted-by":"crossref","first-page":"50155","DOI":"10.18632\/oncotarget.16334","volume":"8","author":"Jiang","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ctro.2022.10.014_b0035","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.3892\/etm.2016.3249","article-title":"L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell\/T-cell lymphoma","volume":"11","author":"Bu","year":"2016","journal-title":"Exp Ther Med"},{"issue":"3","key":"10.1016\/j.ctro.2022.10.014_b0040","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00277-014-2228-4","article-title":"Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus l-asparaginase as a first-line therapy improves outcomes in stage III\/IV NK\/T cell-lymphoma, nasal type (NTCL)","volume":"94","author":"Kim","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctro.2022.10.014_b0045","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.2147\/OTT.S116591","article-title":"Radiation dose reduction for patients with extranodal NK\/T-cell lymphoma with complete response after initial induction chemotherapy","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10.1016\/j.ctro.2022.10.014_b0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","article-title":"Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Yahalom","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"51","key":"10.1016\/j.ctro.2022.10.014_b0055","doi-asserted-by":"crossref","first-page":"85584","DOI":"10.18632\/oncotarget.11319","article-title":"Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I\/II extranodal NK\/T-cell lymphoma, nasal type (CISL-1008)","volume":"7","author":"Yoon","year":"2016","journal-title":"Oncotarget"},{"issue":"27","key":"10.1016\/j.ctro.2022.10.014_b0060","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2022.10.014_b0065","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clml.2016.12.003","article-title":"Comparative study of L-asparaginase-based LOP regimen over CHOP regimen before radiotherapy for stage IIE extranodal nasal type NK\/T cell lymphoma: A Study of 2 Centers","volume":"17","author":"Huang","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"10.1016\/j.ctro.2022.10.014_b0070","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1182\/bloodadvances.2018021311","article-title":"Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group","volume":"2","author":"Wu","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.ctro.2022.10.014_b0075","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3960\/jslrt.17018","article-title":"Current treatment approaches for NK\/T-cell lymphoma","volume":"57","author":"Yamaguchi","year":"2017","journal-title":"J Clin Exp Hematop"},{"issue":"3","key":"10.1016\/j.ctro.2022.10.014_b0080","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ijrobp.2015.07.2267","article-title":"Concurrent chemoradiation therapy followed by consolidation chemotherapy for localized extranodal natural killer\/T-cell lymphoma, nasal type","volume":"93","author":"Oh","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctro.2022.10.014_b0085","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2022.10.014_b0090","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.adro.2019.03.010","article-title":"Are higher doses of consolidation radiation therapy necessary in diffuse large B-cell lymphoma involving osseous sites?","volume":"4","author":"Lee","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ctro.2022.10.014_b0095","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1748-717X-7-100","article-title":"Radiotherapy dose-response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapy","volume":"7","author":"Dorth","year":"2012","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2022.10.014_b0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2018.04.026","article-title":"Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK\/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG)","volume":"129","author":"Deng","year":"2018","journal-title":"Radiother Oncol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630822000982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630822000982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:09:22Z","timestamp":1762502962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630822000982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":20,"alternative-id":["S2405630822000982"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2022.10.014","relation":{},"ISSN":["2405-6308"],"issn-type":[{"type":"print","value":"2405-6308"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility of low-dose radiotherapy for patients with stage I\/II extranodal NK-\/T-cell lymphoma, nasal type achieving complete response after l-asparaginase-containing chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2022.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}]}}